| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.23 | 3e-05 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.22 | 0.0001 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | -0.2 | 0.0002 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.15 | 0.01 |
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | 0.12 | 0.02 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | -0.12 | 0.06 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | -0.1 | 0.07 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.07 | 0.2 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | 0.069 | 0.2 |
| mRNA | TAE684 | CCLE | pan-cancer | AAC | -0.064 | 0.3 |